Literature DB >> 18163959

Isolation and identification of cancer stem-like cells from murine melanoma cell lines.

Jun Dou1, Meng Pan, Ping Wen, Yating Li, Quan Tang, Lili Chu, Fengshu Zhao, Chuilian Jiang, Weihua Hu, Kai Hu, Ning Gu.   

Abstract

In current study, cancer stem-like cells in the murine melanoma B16F10 cells were investigated. CD phenotypes of the B16F10 cells were analyzed by flow cytometry, and the specific CD phenotype cells from the B16F10 cells were isolated by MACS. Then we used colony formation assay in soft agar media, the cell growth assay in serum-free culture media as well as the tumorigenicity investigation of the specific CD phenotype cells in C57BL/6 mice, respectively, to identify cancer stem-like cells in the B16F10 cells. The results showed that the B16F10 cells could form spherical clones in serum-free culture media, and the rate of clonegenesis of CD133+, CD44+ and CD44+CD133+ cells was higher than that of CD133-, CD44- and CD44+CD133- cells in soft agar media, respectively. The tumorigenic potential of CD133+, CD44+, CD44+CD133+ cells and CD44+CD133+CD24+ cells was stronger than that of CD133-, CD44-, CD44+CD133- cells and CD44+CD133+CD24- cells in mice, respectively. In conclusion, the CD44+CD133+CD24+ cells have some biological properties of cancer stem-like cells or are highly similar to the characteristics of cancer stem cells (CSC). These results provide an important method for identifying cancer stem-like cells in B16F10 cells and for further cancer target therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18163959

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  58 in total

1.  Emerging strategies for the identification and targeting of cancer stem cells.

Authors:  Jun Dou; Ning Gu
Journal:  Tumour Biol       Date:  2010-03-25

2.  Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  World J Clin Oncol       Date:  2012-03-10

3.  MiRNA-34a overexpression inhibits multiple myeloma cancer stem cell growth in mice by suppressing TGIF2.

Authors:  Songyan Wu; Xiangfeng He; Miao Li; Fangfang Shi; Di Wu; Meng Pan; Mei Guo; Rong Zhang; Shouhua Luo; Ning Gu; Jun Dou
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

4.  Antitumor efficacy of viable tumor vaccine modified by heterogenetic ESAT-6 antigen and cytokine IL-21 in melanomatous mouse.

Authors:  Xiangfeng He; Jing Wang; Fengshu Zhao; Fangliu Yu; Dengyu Chen; Kai Cai; Cuiping Yang; Junsong Chen; Jun Dou
Journal:  Immunol Res       Date:  2012-06       Impact factor: 2.829

5.  An embryo-specific expressing TGF-β family protein, growth-differentiation factor 3 (GDF3), augments progression of B16 melanoma.

Authors:  Nobuyuki Ehira; Hiroyuki Oshiumi; Misako Matsumoto; Takeshi Kondo; Masahiro Asaka; Tsukasa Seya
Journal:  J Exp Clin Cancer Res       Date:  2010-10-15

Review 6.  Cancer stem cells: lessons from melanoma.

Authors:  Caterina La Porta
Journal:  Stem Cell Rev Rep       Date:  2008-12-18       Impact factor: 5.739

7.  Decreasing lncRNA HOTAIR expression inhibits human colorectal cancer stem cells.

Authors:  Jun Dou; Yaoyao Ni; Xiangfeng He; Di Wu; Miao Li; Songyan Wu; Rong Zhang; Mei Guo; Fengsu Zhao
Journal:  Am J Transl Res       Date:  2016-01-15       Impact factor: 4.060

8.  CD133+ anaplastic thyroid cancer cells initiate tumors in immunodeficient mice and are regulated by thyrotropin.

Authors:  Susan Friedman; Min Lu; Atara Schultz; Dolly Thomas; Reigh-Yi Lin
Journal:  PLoS One       Date:  2009-04-30       Impact factor: 3.240

Review 9.  Stemming cancer: functional genomics of cancer stem cells in solid tumors.

Authors:  C R A Regenbrecht; H Lehrach; J Adjaye
Journal:  Stem Cell Rev       Date:  2008-12       Impact factor: 5.739

Review 10.  Recent advances on skin-resident stem/progenitor cell functions in skin regeneration, aging and cancers and novel anti-aging and cancer therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  J Cell Mol Med       Date:  2009-09-01       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.